| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
36,340,000 |
| Market
Cap: |
45.79(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.26 - $1.26 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Forte Biosciences is a biopharmaceutical company that had been advancing through clinical trials its product candidate, FB-401, which is a topical live biotherapeutic for the treatment of inflammatory skin diseases, including pediatric and adult patients with atopic dermatitis. Co. also has been developing its FB-102 program that addresses certain autoimmune diseases such as vitiligo and alopecia areata.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
118,865 |
118,865 |
218,865 |
| Total Buy Value |
$0 |
$75,040 |
$75,040 |
$179,712 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
9 |
9 |
11 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hasnain Faheem |
Director |
– • – |
2019-05-30 |
4 |
B |
$4.59 |
$200,315 |
I/I |
43,000 |
245,857 |
2.1 |
- |
|
| Duvall Martin J |
Chief Executive Officer |
• • – |
2019-05-28 |
4 |
B |
$4.34 |
$21,679 |
D/D |
5,000 |
13,605 |
2.81 |
- |
|
| Foletta Mark G |
EVP & Chief Financial Officer |
• – – |
2019-05-28 |
4 |
B |
$4.30 |
$21,475 |
D/D |
5,000 |
15,042 |
2.74 |
- |
|
| Gruber Harry E |
President, Science&Innovation |
• • – |
2019-05-24 |
4 |
B |
$4.56 |
$22,783 |
D/D |
5,000 |
9,744 |
2.81 |
- |
|
| Jolly Douglas |
EVP, Research & Pharm Devel |
• – – |
2018-12-10 |
4 |
A |
$8.19 |
$5,995 |
D/D |
732 |
393,478 |
|
- |
|
| Jolly Douglas |
EVP, Research & Pharm Devel |
• – – |
2018-06-08 |
4 |
A |
$8.19 |
$5,758 |
D/D |
703 |
392,746 |
|
- |
|
| Das Asha |
SVP & Chief Medical Officer |
• – – |
2017-12-08 |
4 |
A |
$8.50 |
$21,250 |
D/D |
2,500 |
5,000 |
|
- |
|
| Duvall Martin J |
Chief Executive Officer |
• • – |
2017-12-08 |
4 |
A |
$8.50 |
$21,250 |
D/D |
2,500 |
6,071 |
|
- |
|
| Foletta Mark G |
EVP & Chief Financial Officer |
• – – |
2017-12-08 |
4 |
A |
$8.50 |
$21,250 |
D/D |
2,500 |
7,500 |
|
- |
|
| Jolly Douglas |
EVP, Research & Pharm Devel |
• – – |
2017-12-08 |
4 |
A |
$8.50 |
$6,282 |
D/D |
739 |
392,043 |
|
- |
|
| Gruber Harry E |
President, Research & Devel |
• • – |
2017-12-08 |
4 |
A |
$8.50 |
$21,250 |
D/D |
2,500 |
2,500 |
|
- |
|
| Gruber Harry E |
President, Research & Devel |
• • – |
2017-04-19 |
4 |
B |
$10.00 |
$250,000 |
I/I |
25,000 |
417,753 |
2.66 |
- |
|
| Foletta Mark G |
EVP & Chief Financial Officer |
• – – |
2017-04-19 |
4 |
B |
$10.00 |
$50,000 |
D/D |
5,000 |
5,000 |
2.74 |
- |
|
| Das Asha |
SVP & Chief Medical Officer |
• – – |
2017-04-19 |
4 |
B |
$10.00 |
$25,000 |
D/D |
2,500 |
2,500 |
2.74 |
- |
|
| Duvall Martin J |
Chief Executive Officer |
• • – |
2017-04-19 |
4 |
A |
$10.00 |
$35,710 |
D/D |
3,571 |
3,571 |
|
- |
|
| Berger Franklin M |
Director |
– • – |
2017-04-19 |
4 |
A |
$10.00 |
$253,350 |
D/D |
25,335 |
25,335 |
|
- |
|
| Schimmel Paul |
Director |
– • – |
2017-04-19 |
4 |
B |
$10.00 |
$100,000 |
I/I |
10,000 |
13,623 |
2.1 |
- |
|
| Schimmel Paul |
Director |
– • – |
2017-04-19 |
4 |
A |
$0.00 |
$0 |
I/I |
11,363 |
3,623 |
|
- |
|
| Schimmel Paul |
Director |
– • – |
2017-04-19 |
4 |
A |
$0.00 |
$0 |
D/D |
23,464 |
23,464 |
|
- |
|
| Hasnain Faheem |
Director |
– • – |
2017-04-19 |
4 |
B |
$10.00 |
$1,000,000 |
I/I |
100,000 |
202,857 |
2.1 |
- |
|
| Hasnain Faheem |
Director |
– • – |
2017-04-19 |
4 |
A |
$10.00 |
$1,028,570 |
I/I |
102,857 |
102,857 |
|
- |
|
| Jolly Douglas |
EVP, Research & Pharm DevelOff |
• – – |
2017-04-12 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
43,478 |
|
- |
|
| Jolly Douglas |
EVP, Research & Pharm DevelOff |
• – – |
2017-04-12 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
391,304 |
|
- |
|
| Berman Dennis N |
EVP, Corp DevelopmentOfficer |
• • – |
2017-04-12 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
246,376 |
|
- |
|
| Darcy Thomas E |
Executive Vice PresidentOffice |
• • – |
2017-04-12 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
369,565 |
|
- |
|
76 Records found
|
|
Page 3 of 4 |
|
|
